Related references
Note: Only part of the references are listed.Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia
Michael W. Deininger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study
Michele Baccarani et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase
Michael Lauseker et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
B. Hanfstein et al.
LEUKEMIA (2014)
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
Lorenzo Falchi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Susan Branford et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
T. D. Kim et al.
LEUKEMIA (2013)
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
F. J. Giles et al.
LEUKEMIA (2013)
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors
Massimo Breccia et al.
LEUKEMIA RESEARCH (2013)
The safety profile of imatinib in CML and GIST: long-term considerations
Eirini Thanopoulou et al.
ARCHIVES OF TOXICOLOGY (2012)
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
B. Hanfstein et al.
LEUKEMIA (2012)
Standardized definitions of molecular response in chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2012)
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
Alice Fabarius et al.
BLOOD (2011)
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
Bengt Simonsson et al.
BLOOD (2011)
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
Joerg Hasford et al.
BLOOD (2011)
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
Carlo Gambacorti-Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Hagop M. Kantarjian et al.
LANCET ONCOLOGY (2011)
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
E. Jabbour et al.
LEUKEMIA (2011)
Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia
M. Pfirrmann et al.
LEUKEMIA (2011)
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
Susanne Saussele et al.
BLOOD (2010)
Dysregulation of bone remodeling by imatinib mesylate
Kate Vandyke et al.
BLOOD (2010)
Uncommon or Delayed Adverse Events Associated With Imatinib Treatment for Chronic Myeloid Leukemia
Rishard Salie et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia.
Claude Preudhomme et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Management of Drug Toxicities in Chronic Myeloid Leukaemia
Michael J. Mauro et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Harmonization of molecular monitoring of CML therapy in Europe
M. C. Mueller et al.
LEUKEMIA (2009)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2009)
Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
Timothy P. Hughes et al.
BLOOD (2008)
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Richard A. Larson et al.
BLOOD (2008)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford et al.
BLOOD (2008)
Long-term imatinib therapy promotes bone formation in CML patients
Stephen Fitter et al.
BLOOD (2008)
Congestive heart failure is a rare event in patients receiving imatinib therapy
Ehab Atallah et al.
BLOOD (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
Altered bone and mineral metabolism in patients receiving imatinib mesylate
E Berman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
